Artivion, Inc. (AORT)
- Previous Close
20.27 - Open
20.24 - Bid 20.51 x 800
- Ask 20.46 x 1000
- Day's Range
20.24 - 20.60 - 52 Week Range
12.16 - 21.90 - Volume
81,513 - Avg. Volume
221,417 - Market Cap (intraday)
857.971M - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.75 - Earnings Date May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 9, 2015
- 1y Target Est
24.08
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
artivion.comRecent News: AORT
Performance Overview: AORT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AORT
Valuation Measures
Market Cap
845.46M
Enterprise Value
1.14B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.33
Price/Book (mrq)
3.00
Enterprise Value/Revenue
3.23
Enterprise Value/EBITDA
42.74
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.67%
Return on Assets (ttm)
1.21%
Return on Equity (ttm)
-10.84%
Revenue (ttm)
354M
Net Income Avi to Common (ttm)
-30.57M
Diluted EPS (ttm)
-0.75
Balance Sheet and Cash Flow
Total Cash (mrq)
58.94M
Total Debt/Equity (mrq)
127.17%
Levered Free Cash Flow (ttm)
13.06M
Research Analysis: AORT
Company Insights: AORT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: AORT
AORT: Raising target price to $22.00
ARTIVION INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetAORT: Lowering target price to $21.00
ARTIVION INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetAORT: Raising target price to $23.00
ARTIVION INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetAORT: What does Argus have to say about AORT?
ARTIVION INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target